2025-20290Notice

NIH Grants Biotech Firm Monopoly on Cutting-Edge Cancer Detection Tech

Published Date: 11/19/2025

Notice

Summary

The National Institutes of Health plans to give BioncoDx, LLC an exclusive license to use special methods for diagnosing and predicting cancer. This means BioncoDx will have the sole right to develop and sell these cancer-related technologies. If you want to comment or apply for a license, you need to act by December 4, 2025.

Analyzed Economic Effects

3 provisions identified: 1 benefits, 2 costs, 0 mixed.

Exclusive Urine-Based Cancer Test License

The NIH plans to grant BioncoDx, LLC an exclusive license to develop, manufacture, and commercialize Food and Drug Administration (FDA) premarket approval tests that use four urine biomarkers—creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid—to detect and prognose cancers (examples listed include lung, breast, colorectal, kidney/bladder, prostate, liver, stomach, pancreatic, GYN, and brain). The notice describes this technology as a unique, non-invasive screening and diagnostic tool that can detect cancers at an early stage using urine samples and that urine sampling minimizes patient discomfort compared with invasive methods.

Sole Commercial Rights for BioncoDx

The prospective license would give BioncoDx the sole (exclusive) right to practice the listed patent rights worldwide where patent rights exist for the specified field of use: developing, manufacturing, and commercializing FDA PMA tests using the named biomarkers for screening/diagnosing the listed cancers. After a negotiated period, the exclusive field of use will be reduced to a subset of three cancer indications and will include strict developmental benchmarks for each indication.

Prospective License Will Be Royalty‑Bearing

The notice states the prospective exclusive license will be royalty-bearing. The notice also states that the license may be granted unless, within fifteen (15) days from the date of the published notice, the National Cancer Institute receives written evidence and argument that the grant would not be consistent with applicable law.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
11/19/2025
12/4/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in